Table 1 Clinicopathological and molecular characteristics of the SCAN-B discovery and validation cohorts
From: The DNA methylation landscape of primary triple-negative breast cancer
Discovery cohorta | Validation cohorta | |
---|---|---|
Number of patients | ||
235 | 136 | |
Patients assessable for DRFI after adjuvant therapy | ||
144 | Not applicable | |
Age (median and range, in years) | ||
62 (26–91) | 62.5 (30–95) | |
Lymph node status | ||
Node-negative (N0) | 152 (65%) | 87 (69%) |
Node-positive (N+) | 83 (35%) | 39 (31%) |
Not available | 0 | 10 |
Nottingham Histologic Grade | ||
G1 | 0 (0%) | 0 (0%) |
G2 | 26 (11%) | 24 (23%) |
G3 | 206 (89%) | 81 (77%) |
Not available | 3 | 31 |
PAM50 subtype | ||
Basal-like | 187 (80%) | 95 (70%) |
non-Basal-like | 48 (20%) | 41 (30%) |